Welcome to our dedicated page for Lixte Biotechnology Hldgs news (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Hldgs stock.
Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) maintains this comprehensive news hub for investors tracking developments in its clinical-stage cancer therapeutics. Our curated collection features official press releases, regulatory filings, and material event announcements related to the company’s protein phosphatase inhibitor pipeline.
This resource enables stakeholders to monitor critical updates including clinical trial progress for lead compound LB-100, financial disclosures, and strategic collaborations. All content is sourced directly from company communications and SEC filings to ensure reliability.
Key categories include Phase 1/2 trial results, intellectual property milestones, executive leadership changes, and quarterly earnings reports. Bookmark this page for timely access to investment-relevant developments in Lixte’s novel approach to enhancing chemotherapy and radiation efficacy through targeted phosphatase inhibition.
LIXTE Biotechnology Holdings has appointed Dr. Jan Schellens as the new Chief Medical Officer, effective August 1, 2024, succeeding Dr. James S. Miser.
Dr. Schellens brings over 25 years of clinical experience in oncology and pharmacology, including leadership roles at prominent institutions like the Netherlands Cancer Institute.
He is expected to significantly contribute to LIXTE's development of LB-100, which aims to enhance chemotherapy and immunotherapy treatments. Dr. Schellens has co-authored over 900 scientific publications and has had significant roles on various medical boards and advisory committees.
LIXTE CEO Bas van der Baan expressed confidence in Dr. Schellens' ability to drive the company's growth and development in cancer therapeutics.
LIXTE Biotechnology provided an update on their recent activities. Key highlights include promising pre-clinical data on their compound LB-100 in a new field of cancer biology called 'activation lethality.' The findings suggest that LB-100 can force cancer cells to lose their cancer-causing properties, potentially opening new treatment strategies alongside ongoing clinical trials in lung, ovarian, and sarcoma cancers. The data was presented by Dr. René Bernards at a major cancer research conference and published in the journal Cancer Discovery.
CEO Bas van der Baan presented at the MedInvest Biotech and Pharma Investor Conference. LIXTE co-sponsored an international workshop at Harvard’s Dana Farber Cancer Institute, discussing innovative cancer therapy approaches. Clinical trials for LB-100 are underway at various prestigious institutions, including the University of Texas MD Anderson Cancer, City of Hope Cancer Center, Sarah Cannon Research Institute, and the Spanish Sarcoma Group. In February 2024, LIXTE signed an exclusive patent license agreement with the NIH. The company's latest financial data is available in their quarterly report filed with the SEC.
LIXTE Biotechnology Holdings, a clinical stage pharmaceutical company, is co-sponsoring an international scientific conference on "Therapeutic Over-Activation in Cancer" at Harvard University's Dana Farber Cancer Institute. The conference will discuss LIXTE's lead clinical compound, LB-100, which has shown promising results in triggering hyper-activation of signals leading to the death of cancer cells. LIXTE's unconventional approach to cancer therapy is based on over-activating oncogenic signaling, presenting a new treatment strategy in cancer therapy.
FAQ
What is the current stock price of Lixte Biotechnology Hldgs (LIXT)?
What is the market cap of Lixte Biotechnology Hldgs (LIXT)?
